Corrigendum: In vivo total or partial hepatectomy followed by ex vivo liver resection and autotransplantation for malignant tumors: a single center experience

Shaoyan Xu,Chenlu Hu,Zedong Jiang,Guogang Li,Bo Zhou,Zhenzhen Gao,Weilin Wang,Sheng Yan

DOI: https://doi.org/10.3389/fonc.2023.1251636

IF: 4.7

2023-08-11

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1214451.].

oncology

What problem does this paper attempt to address?

Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Lanlan Xiao,Xingqi Xu,Kaizhou Huang,Yalei Zhao,Lingjian Zhang,Lanjuan Li

DOI: https://doi.org/10.1155/2021/9875940

2021-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2019/3757149.].
Correction: Intrahepatic Tissue Implantation Represents a Favorable Approach for Establishing Orthotopic Transplantation Hepatocellular Carcinoma Mouse Models

Quan Rao,A‐Bin You,Zhan Guo,Bingfeng Zuo,Xianjun Gao,Ti Zhang,Du Zhi,Chenxuan Wu,HaiFang Yin

DOI: https://doi.org/10.1371/journal.pone.0206322

IF: 3.7

2018-01-01

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0148263.].
Erratum: Hepatic Carcinoma with Indolent T-lymphoblastic Proliferation (It-Lbp).

Mei Kong,Zhaoming Wang,Xiaodong Teng,Liming Xu,Jimin Liu,Chenyang Jiang,Lisong Teng

2019-01-01

Abstract:[This corrects the article on p. 1674 in vol. 11, PMID: 31938268.].
Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma

Yongrong Lei,Xishu Wang,Heng Sun,Yuna Fu,Yichen Tian,Ludi Yang,Jianhua Wang,Feng Xia

DOI: https://doi.org/10.3389/fonc.2024.1438731

2024-07-10

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.601668.].
Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Qiao Ke,Fuli Xin,Huipeng Fang,Yongyi Zeng,Lei Wang,Jingfeng Liu

DOI: https://doi.org/10.3389/fimmu.2022.952446

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.913464.].
Corrigendum: Lymphatic Reconstruction in Kidney Allograft Aggravates Chronic Rejection by Promoting Alloantigen Presentation

Jinwen Lin,Ying Chen,Huijuan Zhu,Kai Cheng,Huiping Wang,Xianping Yu,Mengmeng Tang,Jianghua Chen

DOI: https://doi.org/10.3389/fimmu.2022.1071763

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.796260.].
Corrigendum: Immune Tolerance Induced by Hematopoietic Stem Cell Infusion after HLA Identical Sibling Kidney Transplantation

Hongfeng Huang,Qixia Shen,Jingyi Zhou,Xiuyan Yang,Qiuqin Cai,Jia Shen,Shi Feng,Wenqing Xie,Hong Jiang,Jianghua Chen

DOI: https://doi.org/10.3389/fimmu.2022.1052676

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.995243.].
Corrigendum to “system Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma”

Jun Xu,Yongjun Guan,Zhendong Qiu,Xin Zhang,Zi Liu,Yu Zhou,Chen,Jia Yu,Yi Chao Zhang,Weixing Wang

DOI: https://doi.org/10.1155/2022/9875295

2022-01-01

Oxidative Medicine and Cellular Longevity

Abstract:[This corrects the article DOI: 10.1155/2021/6485871.].
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

Lei Zhang,Zhi-Ping Yan,Zhong-Heng Hou,Peng Huang,Min-Jie Yang,Shuai Zhang,Shen Zhang,Shao-Hua Zhang,Xiao-Li Zhu,Cai-Fang Ni,Qiang Li

DOI: https://doi.org/10.3389/fmolb.2021.727969

IF: 6.113

2021-08-30

Frontiers in Molecular Biosciences

Abstract:[This corrects the article DOI: 10.3389/fmolb.2021.624366.].

biochemistry & molecular biology
Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Wen-Jie Wu,Qian Liu,Pu-Gen An,Lin Wang,Jian-Yun Zhang,Yan Chen,Tong Zhang,Jie Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1346845

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1282629.].
[Corrigendum] Combined antitumor effects of P‑5m octapeptide and 5‑fluorouracil on a murine model of H22 hepatoma ascites

Xiao Han,Liping An,Dongmei Yan,Hiroshi Matsuura,Weiguang Ding,Mengchuan Zhang,Guangyu Xu,Ying Sun,Guangxin Yuan,Manli Wang,Nanxi Zhao,Jingbo Sun,Xun Zhu,Peige Du

DOI: https://doi.org/10.3892/etm.2018.6971

IF: 2.7

2019-01-01

Experimental and Therapeutic Medicine

Abstract:[This corrects the article DOI: 10.3892/etm.2018.6422.].
Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells

Tao Li,Xinlong Lin,Binhai Shen,Wujian Zhang,Yangyang Liu,Hongbin Liu,Ye Wang,Lijun Zheng,Fachao Zhi

DOI: https://doi.org/10.3389/fimmu.2023.1139000

IF: 7.3

2023-02-22

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.1047570.].

immunology
Corrigendum to “ethyl Pyruvate Ameliorates Hepatic Ischemia-Reperfusion Injury by Inhibiting Intrinsic Pathway of Apoptosis and Autophagy”

Song Miao,Jie Lü,Weiqi Dai,Wei Fan,Ling Xu,Kan Chen,Lei He,Ping Cheng,Yan Zhang,Chengfen Wang,Dong Wu,Jing Yang,Rong Zhu,Huawei Zhang,Yingqun Zhou,Chuanyong Guo

DOI: https://doi.org/10.1155/2016/5434275

2016-01-01

Mediators of Inflammation

Abstract:[This corrects the article DOI: 10.1155/2013/461536.].
Correction To: Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial

Shaohua Li,Jie Mei,Qiaoxuan Wang,Zhixing Guo,Lianghe Lu,Yihong Ling,Li Xu,Minshan Chen,Lie Zheng,Wenping Lin,Jingwen Zou,Yang Wen,Wei,Rong‐Ping Guo

DOI: https://doi.org/10.1245/s10434-021-09813-2

IF: 4.339

2021-01-01

Annals of Surgical Oncology

Abstract:A correction to this paper has been published: https://doi.org/10.1245/s10434-021-09813-2
Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Qi Chang Zheng,Shuai Jiang,Yu Zhe Wu,Dan Shang,Yong Zhang,Shao Bo Hu,Xiang Cheng,Chen Zhang,Ping Sun,Yang Gao,Zi Fang Song,Min Li

DOI: https://doi.org/10.3389/fbioe.2021.656268

IF: 5.7

2021-02-11

Frontiers in Bioengineering and Biotechnology

Abstract:[This corrects the article DOI: 10.3389/fbioe.2020.00512.].

multidisciplinary sciences
Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Thomas Morgan Hulen,Christina Friese,Nikolaj Pagh Kristensen,Joachim Stoltenborg Granhøj,Troels Holz Borch,Marlies J W Peeters,Marco Donia,Mads Hald Andersen,Sine Reker Hadrup,Inge Marie Svane,Özcan Met

DOI: https://doi.org/10.3389/fimmu.2024.1462081

2024-07-18

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1180997.].
Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity

Hao Zheng,Wen-juan Zheng,Zhen-guang Wang,Yuan-ping Tao,Zhi-ping Huang,Le Yang,Liu Ouyang,Zhi-qing Duan,Yi-nuo Zhang,Bo-ning Chen,Dai-min Xiang,Gang Jin,Lu Fang,Fan Zhou,Bo Liang

DOI: https://doi.org/10.3389/fimmu.2022.1093403

IF: 7.3

2022-12-08

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.845193.].

immunology
Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Haibo Xing,Mengting Tong,Jing Wang,Hanqing Hu,Chongya Zhai,Chunhui Huang,Da Li

DOI: https://doi.org/10.1155/2022/9767389

2022-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2018/3195025.].
Corrigendum: Lipid metabolism and tumor immunotherapy

Yue Wang,Zongjin Guo,Adamu Danbala Isah,Shuangwei Chen,Yongfei Ren,Huazhong Cai

DOI: https://doi.org/10.3389/fcell.2024.1349379

IF: 5.5

2024-01-26

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2023.1187989.].

cell biology,developmental biology

Corrigendum: In vivo total or partial hepatectomy followed by ex vivo liver resection and autotransplantation for malignant tumors: a single center experience

Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Correction: Intrahepatic Tissue Implantation Represents a Favorable Approach for Establishing Orthotopic Transplantation Hepatocellular Carcinoma Mouse Models

Erratum: Hepatic Carcinoma with Indolent T-lymphoblastic Proliferation (It-Lbp).

Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma

Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Corrigendum: Lymphatic Reconstruction in Kidney Allograft Aggravates Chronic Rejection by Promoting Alloantigen Presentation

Corrigendum: Immune Tolerance Induced by Hematopoietic Stem Cell Infusion after HLA Identical Sibling Kidney Transplantation

Corrigendum to “system Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma”

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

[Corrigendum] Combined antitumor effects of P‑5m octapeptide and 5‑fluorouracil on a murine model of H22 hepatoma ascites

Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells

Corrigendum to “ethyl Pyruvate Ameliorates Hepatic Ischemia-Reperfusion Injury by Inhibiting Intrinsic Pathway of Apoptosis and Autophagy”

Correction To: Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial

Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity

Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Corrigendum: Lipid metabolism and tumor immunotherapy